Evotec SE (NASDAQ:EVO) Short Interest Down 18.0% in April

Evotec SE (NASDAQ:EVO - Get Free Report) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 660,800 shares, a decrease of 18.0% from the March 31st total of 806,300 shares. Based on an average trading volume of 83,600 shares, the days-to-cover ratio is presently 7.9 days. Approximately 0.2% of the company's stock are sold short.

Institutional Trading of Evotec

Several institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new position in shares of Evotec in the 4th quarter worth approximately $27,000. CSS LLC IL purchased a new position in Evotec in the 4th quarter worth about $50,000. Bank of America Corp DE lifted its stake in Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after buying an additional 9,289 shares in the last quarter. Lighthouse Investment Partners LLC acquired a new stake in shares of Evotec during the fourth quarter valued at approximately $166,000. Finally, DCF Advisers LLC boosted its stake in Evotec by 5.9% in the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock worth $956,000 after purchasing an additional 12,816 shares during the period. Institutional investors and hedge funds own 5.81% of the company's stock.

Evotec Stock Performance

Shares of Evotec stock traded up $0.01 on Wednesday, reaching $4.06. 289,782 shares of the company were exchanged, compared to its average volume of 85,495. Evotec has a 1-year low of $2.84 and a 1-year high of $5.68. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43. The company's 50-day moving average is $3.61 and its two-hundred day moving average is $4.15.

Analysts Set New Price Targets

Separately, Deutsche Bank Aktiengesellschaft upgraded shares of Evotec from a "sell" rating to a "hold" rating in a research note on Thursday, April 24th.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.